Biosimilars Mark Milestone In Europe With Regulators' Nod

Law360, New York (June 28, 2013, 3:53 PM EDT) -- European regulators on Thursday recommended approval of biosimilar drugs from Hospira Inc. and Celltrion Inc. that are more complex than any others previously cleared for sale, a milestone that heralds possible patent suits and serious competition for pricey brand-name biologics.

The blessing from a committee of the European Medicines Agency marks the first time so-called monoclonal antibody biosimilars have won endorsement in a developed region. If formal approval comes through for the biosimilar version of infliximab — known as Inflectra at Hospira and Remsima at Celltrion...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.